	'Please type a plus sign (+) insi	→ [+]			3	PTO/SB/08A (08-00)
_	Under the Paperwork Reduction	ACL POS LO POSAS	are inquired	App U.S. Patent and Trade to respond to a collection of	roved for use through 10 mark Office: U.S. DEPAI finformation unless it contain	/31/2002. OMB 0651-0031 RTMENT OF COMMERCE s a valid OMB control number
	Substitute for form 1449A/PTO	/ -	8		Complete if Kno	
	SUPPLEMENTAL	MAY 0 7 20	Z Applica	ition Number	09/281,474	
	INFORMATION DISCLO	SURE	Fang		March 30, 199	99
	STATEMENT BY APPL	ICANT	od Filst N	amed Inventor	Rajopadhye	
	Sheet 1 of 1		Attorne	y Docket Number	DM-6958	

			U.S. PATENT DOCU	MENTS			
F		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages California Lines Manua Balanca		
Examiner Initials *	Cite No. ¹	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
7		US6143274	Tweedle et al.	11-07-00			
		ļ					
		 			- OFN/ED		
··		 	COPY OF PAI	PERS	RECEIVED		
			ORIGINALLY		0.0002		
					MAY 1 0 2002		
					20010001		
					TECH CENTER 1600/290		
					TECTIOE		
					† <u>-</u>		
							

	FOREIGN PATENT DOCUMENTS Foreign Patent Document Name of Patentee Date of Publication of Pages, Columns, Lines,														
Examiner	Cite	For	eign Patent D	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	l .							
Initials*	No.1	Office ³	Number ^a	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₀							
	ļ							4.							
		 						<u> </u>							
		+		1			*************************************	<u> </u>							
	<u> </u>	 													
	 					·		ļ							
		 						-							
		†	 												

Examiner Signature Date Considered (J36 0)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

•			•.									·	Shee	et <u>1</u>	of <u>7</u>	
Form P	TO-14	40			II S	DE	PAI	RTN	1ENT	OF COMME	ICE	ATTY. DOCKET NO		SERIAL	NO.	
(Reprod	luced)		•		Þ.	ATE	NT	ANI) TR	ademarik of		DM-6958		09/281	<u>,474 </u>	
V	INFO	ORMA'	TIO	N D	ISC	CLC	วรเ	JRE	E ST	ATEMENT	16. 2C.131	APPLICANT RAJOPADHYE ET	ΓΔΙ			İ
	•									CET 1 6	2000	FILING DATE		GROU		
		(Lloc		3Y /						(sally)	2000	March 30, 1999		1616		
		(USE	Sev	I S	. P	ATI	EN'	T D	OC	UMÄNTS	940					
*EXAMIN	NER		DOG							DATE TRAD	BNYOWE		CLASS	SUB-	FILING DA APPROPR	
INITIAL			 1	1		—т			_				 	OLAGO	71110111	
The	20	AA	4	2	4	8	8	0	2	2/3/81	KUNTZ					
/_	1	AA	4	-	7	-		-		27070.	1,001,11					Ì
	1	AB	4	4	7	2	5	o	9	9/18/84	GANSC	W ET AL.				
	1										,					}
		AC	4	5	3	6	3	8	7	8/20/85	SAKAM	OTO ET AL.				
					_		_	_	_	0/00/00	TONE	•				
7	<u> </u>	AD	4	8	5	9	7	7	<u>7</u>	8/22/89	TONEF					
7	\mathcal{C}	A.E.		0	8	Ω	Ω	2	7	1/29/91	BERGS	TEIN ET AL				
<i>/</i>	7	AE	4 F							OCUMENT						
		T		CU						DATE	COUNT	RY	CLASS	1		
			İ											CLAS	S YES	NO
,	$\overline{\wedge}$								_					-	_	1 1
		AF	8	1_	0	1	1	4	5_	4/30/81	wo			+		
l	(1.0				3	8	0	1	4/19/90	wo			.		
-		AG	9	0_	0	13	10	-	-	4/19/30	"				-	
1 1		AH	9	0	0	5	5	3	9	5/31/90	wo					1
1	AI 9 0 1 2 5 8 5 11/1/90 WO															+
											1			-		
		AJ	9	0	1	3	3	0	0	11/15/90	wo_				_	1
1 1		1						1	4	02/07/91	wo			- -	`	
$\vdash \forall$		AK	9	1	0	1	1	14	4	02/01/91	1					
i Y		AL	9	1	1	5	2	4	4	10/17/91	wo					
10		+~-	† <u> </u>	╫	\top	<u> </u>	T	Т						_ -	-	
1 1	<u> </u>	AM	9	1	1	4	4	6	0	10/3/91	<u>wo</u>			_l		
	$-\mathcal{T}$										a . a.	diversit Berese Etc.)				i
	$\overline{}$		<u>oc</u>	<u>UM</u>	<u>EN</u>	<u>TS</u>	(In	cluc	ling	Author, litle,	Date, Per	tinent Pages, Etc.)				
DY	()	AN			lub	bric	n e	et a	I, LI	ebigs Ann. C	Allein. 13	79 , 776-783				
1	\mathcal{A}	AO		╁)eC	irac	to a	and	Kai	ser. J. Org.	Chem. 1	980 , 45, 1295				
	,	^		ı							_					
\vdash		AP		Tj	I. D	ene	eka	mp	et a	al., 1982 , Br.	. J. Canc	er, <i>45</i> , 136-139				
L1													<u> </u>			
		AQ	_	ן ב	Den	eka	amı	p ef	al.,	1982 , Br. J	. Cancer	<i>46</i> , 711 – 720				
	├	45		4.	<u> </u>		e+	-1	100	2 Moth ⊑n	zvmology	<i>y, 93</i> , 280-333				
ŀ		AR		19	hc	se	et	al.,	198	o, iviet⊓. ⊏N	zymology	, <i>50</i> , 200-000				
-		AS		+)en	eka	mr	19	84. Acta Ba	diologica	Oncology, 23 Fas	c. 4, 217 –	225		
		70														
	AT Hans-Hermann Hagemeier et al., 1986, Int. J. Cancer, 38, 481-488 RECEIVED AU Margerstadt et al., Magn. Reason. Med., 1986, 3, 808 EXAMINER DATE CONSIDERED															
	<u>V</u>			- 1											TIEC	EIVE
7	X	AU		TI	Mai	rge	rsta	ıdt	et a	I., Magn. Re	ason. Me	ed., 1986, 3, 808				
1_2	1	<u></u>	<u> </u>									DATE CONSIDERI	ED		- 007 1	8 20nre
EXA	MIŇEF	۲ 🔎	\ /									1	1 .			
			L	\ 	D	4	4	2_				(હ)એ	02	n	CH CENTER ion if not in	1666
*EYA	MINER:	Initial i	f citat	tion 4	cons	side	red	who	ether	or not citation	is in confo	mance with MPEP 609;	Draw line thr	ough citat	ion if not in	, pn@\5800
confo	rmance	and not	cons	sider	ed.	Inc	lude	col	by of	this form with I	next comm	unication to applicant.				

•	Sheet 2 of 7 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE Reproduced) PATENT AND TRADE OF THE COMMERCE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT STATEMENT Sheet 2 of 7 ATTY. DOCKET NO. DM-6958 O9/281,474 APPLICANT RAJOPADHYE ET AL														
Form PTO-	1449			U.S	S. D	EP/	ART	MEN	T OF COMME	BCE	1				
(Reproduced	a) PLEME	NTA	ΔI Ι	ŀ NF	OR	EN M	I AN Sti i	ו ואט וו טוי	NSCLOSUI	RE YO	DM-6958 APPLICANT		09/28	1,474	
•			S	TA	TE	ME	NT	•		·	RAJOPADHYE ET	Γ AL			
			BY	AP	PL	IC/	TNA		007 1 6	(بي 2000	FILING DATE		GROU	Р	
	(Us	e se	ver	als	he	ets	it n	ece	SATURNETS		March 30, 1999		1616		
*EXAMINER	1		CUI						DATE PADE	. 0/		CLASS	SUB-	FILING D	
INITIAL		+-	1	т	Γ					<u> </u>			CLASS	APPROP	RIATE
70	} AA	5	0	2	1	2	3	6	6/4/91	GRIES E	ET AL.		_		
7							-								
	AB	5	0	6	4	9	5	6	11/12/91	KRUPE	R ET AL				
.	AC	5		8	7	4	4	0	2/11/92	CACHE	RIS ET AL				
</td <td> ^</td> <td>+</td> <td> </td> <td> </td> <td><u>'</u></td> <td>7</td> <td>-</td> <td></td> <td>2/11/02</td> <td>OAOIILI</td> <td>IIO ET AL</td> <td></td> <td></td> <td></td> <td></td>	 ^	+			<u>'</u>	7	-		2/11/02	OAOIILI	IIO ET AL				
	AD	5	1	5	5	2	1	5	10/13/92	RANNE	Y				
7						_			4/05/04		T A1				
1007	AE	<u>5</u>			1 3N				1/25/94 DOCUMENT	LOVE E	I AL	į		L	
, _			CU						DATE	COUNTR	ΙΥ	CLASS	SUB-		LATION
						1							CLAS	S YES	МО
XX,)	AF	9	2		٦	_	2	9	8/6/92	wo			_		
' 															
AG 9 2 1 7 2 1 5 10/15/92 WO															
	١														
	AH	9	2	1	9	6	4	6_	11/12/92	wo			ļ -	_	<u> </u>
	AI	9	3	0	8	2	1	0	4/29/93	wo				-	
- 1	AJ	9	3	1	7	7	1	5	9/16/93	wo			_		
1											•		1_		
<u>v</u>	AK	9	3	2	3	0	/	4	11/25/93	wo				_	<u> </u>
B	AL	9	4	0	5	3	2	8	4/17/94	wo					
· ·															
	HER D	OCL	_		_				<i>luthor, Title, I</i> ology, 1988,		nent Pages, Etc.)		=		
A	AM		''	ung	je e	zi a	1., 1	iaui	010gy, 1 300 ,	, 100, 000					
T			B	evil	acc	qua	et	al., 1	1987, Proc.	Natl. Acad	d Sci <i>., 84</i> , 9238-924	2			
	AN		В	ous	que	et e	et a	l., R	adiology, 19	88 , 166, 6	93				
	AO														
	AP		K	nov	vles	s et	al.	, 198	87 , Analytica	al Biochen	nistry, 160, 440-443	•			
	AQ		W	/elli	cor	ne	et a	al 1	990. J. Imm	nunol. 144	, 7, 2558-2565.				
	AR		Ju	ulia	na	Dei	nek	amp	o, 1990, Car	ncer Meta.	Rev. 9, 267-282.				
	AS		С	lau	SS 6	et a	ıl., '	1990), Journal of	Biologica	l Chemistry, 265, 12	2, 7078-70	83		
	AT Deshpande, S., et al, J. Nucl. Med. 1990 , 31, 473														
20	AU		В	rec	hbi	el, l	M. a	and	Gansow, O.	, Bioconju	gate Chem. 1991, 2	2, 187			·
EXAMINE	(AMINER DATE CONSIDERED														
			R	\langle	1	<i>ک</i> ر	0 -				(olarlo)				
				_	1)	<u> </u>					APER COO. S				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

• ,	Sheet 3 of 7 orm PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. Reproduced) PATENT AND TRADEMABLY OF BCC DM-6958 09/281,474 SUPPLEMENTAL INFORMATION DISCLOSURE APPLICANT															
												ATTY. DOCKET NO		SERIAL	NO.	
(Reproduce	ed)				P	ATE	NT	AN() TR	ADEMARK OF	BUE			09/281,	474	
SU	PPL	EME.	NTA			DRI TEN			ON C	DISCLOSUF	EC 7C19	APPLICANT RAJOPADHYE E	ΤΔΙ			
			R							not 1	رين اين	FILING DATE	I AL	I GROUP		
		(Use							ces	CCT 1	0 ZUUU	March 30, 1999		1616		
										JMENTS	. \$7					
*EXAMINE	R		DO	CU	ME	NT	NU	MB	ER	DATE PRAI	ENTINE		CLASS		FILING DA ⁻ IF APPROF	
INITIAL	$\overline{}$		 									<u> </u>	 	CLASS	IF APPROF	TIAIL
\mathcal{N}	الر	AA	5	3	5	0	8	3	7.	9/27/94	BRIDGE	R ET AL				
	71															
		AB	5_	3	7	6	3	5	6	12/27/94	A. C. MC	DRGAN, JR.				
ŀ		۸.	_	2	,	2	7	_	7	0/20/04	CADINI	CHECK ET AL				
- 10	-+'	AC_	5	3	4	2	7	5		8/30/94	GANIN-C	CHESA ET AL.	·			
\checkmark		AD	5	3	8	2	6	5	4	1/17/95	LYLE ET	AL		-		
4													1			
<u>Pe</u>	بلـ(AE	5	4		7				5/23/95	WALLAC	CE	<u></u>			
			_							OCUMENTS		· · · · · · · · · · · · · · · · · · ·	bi 400	hun	TRANCI	ATION
			lpo	CU	ME	NT	ΝU	MR	EH	DATE	COUNTR	Y	CLASS	SUB- CLASS	TRANSL	NO
	_		+											OLAGO	1,5	110
) ,	AF	9	4	1	1	4	9	9	5/26/94	WO (Cor	responds to A21566	20)			
	AG 9 4 2 2 4 9 7 10/13/94 WO(Corresponds to DE9422497)															
	AG 9 4 2 2 4 9 7 10/13/94 WO(Corresponds to DE9422497) AH 9 5 2 5 5 4 3 9/28/95 WO															
- 1																
AI 9 6 3 1 2 4 3 10/10/96 WO																
											·				. 1	
		AJ	9	6	0	0	5	7	4	1/11/96	wo					
		A 1.7		_		_		_		1/05/00			-			
		AK	9	6	U	1	6	5	3	1/25/96	wo					
W	<i>ا</i> ا	AL	9	6	4	1	8	o	3	12/27/96	wo			-		
			•		·							-	•			
			CUN									ent Pages, Etc.)	···			
	(AN	И		Di	Zio	et	al.,	, Bi	ocor	ijugate Chei	m., 1991 ,	<i>2</i> , 353-366.				
$-\Psi$, I	AN	<u>. </u>		B	akk.	or c	at a	.1 1	ifo (Sci., 1991 , 4	10 1583-0	<u>. </u>				
1.	^'	`		"	ann	CIC	51 0	, .	_116 (Jul., 1991, 4	1000-0	' '				
	AC	5		D	vora	ak e	et a	ıl.,	1991	, Cancer Co	ells 3, 77-8	35.				
	1			L									<u></u>			
- 1	AF	?		Oı	rlar	ndo	et	al.	J. of	Biological C	Chemistry,	10/1991 , 266, 29,	19543-19	550.		
	AC	- +		N/1	الميا	lor i	ot s		100	2 Proc Na	tl Acad S	ci USA, <i>89</i> , 11832	11836			
1	1~	•		''''	uen	101	C1 C	aı.,	199	2 , 1 100. Na	iii. Acad O	C. OOA, 03, 11002	-11000			
	AF	7		Br	ect	nbie	el, l	М. а	and (Gansow, O.	, J. Chem	. Soc. Perkin Trans	s. 1992 , <i>1</i> ,	1175		
	<u> </u>					_						· · · · · · · · · · · · · · · · · · ·				
1	AS	3		Βι	ırrc	ws	et	al.,	199	2 , Cancer F	Research,	<i>52</i> , 5954 - 5962				
	 	_		<u> </u>				- T	·1a -a	o (Darah N	lat Assa	CCL LICA 1002	00.0006.0	000)	AFC	
\mathcal{M}	TA			Bu	ırrc	ows	an	ia i	nort	be (Porch. N	iai. Acad.	SCI., USA, 1993,	90, 6996-9	000)	RECE	TAAF
- 																
18/	001 18 2000															
EXAMINE	TEAL A.															
					<u>L</u>	1	ב עני	20	2			10/21/02	-		- LEWICH I	600/2900
*EYAMINED	te leit	ial if all	atio-		cida	L				not citation is in	conforma	ce with MPEP 609; Dra	w line through			
										t communicati			mie unoug	c.a.iOH II		,

March Separation Separati															t 4	of _7_
DATE DATE	·	10 .			11.5	S DI	-PA	RTN		OF COMME	RASE.	ATTY, DOCKET NO.				
SUPPLEMENTAL INFORMATION BISCLOSURE STATEMENT ST	dood\				F	PATI	ENT	ANI	D T	ADEMARK O	FFICE			09/281,4	<u>74</u>	
STATEMENT Use several sheets if newspace FILING DATE FILING DATE GROUP 1616	CLIPPLE	MEI	ATA	LI	NFO	ORI	MA	ΓIO	NE) SCLÓSUI	RE Š		A.1			
CLASS SUB- FILING DATE CLASS SUB-	3011 ==			S	TA"	LEV	NED	1 T		OCT 1 6	2000		AL	CROUR		
CLASS SUB- FILING DATE NAME CLASS SUB- FILING DATE STAME CLASS SUB- FILING DATE STAME CLASS SUB- FILING DATE F			1	BY	ΑP	PL	ICA	NT		P	S					
AA 5 3 9 5 6 0 9 3/7/95 A. W. STUTTLE AB 5 4 0 3 7 1 3 4/4/95 BEVILACQUA ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/28/96 NOSCO ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 5 8 9 3 9 9/4/7/98 FLANAGAN ET AL. FOREIGN PATENT SCUMENTS DOCUMENT NUMBER PATENTS CLASS SUB-TRANSLATION CLASS YES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AN 9 8 1 6 2 5 6 8/23/98 WO AK 9 8 1 6 2 5 6 8/23/98 WO OTHER DOCUMENTS (Including Blor, Title, Date, Pertinent Pages, Etc.) Hu et al., 1994, Cassogy Research, 6, 7, 321-327. AN O'Reilly et al., Cassogy Research,		(Us	e se	ver	al s	she	ets	if ne	eog	ssagy)	<u>8</u> 5/	March 30, 1999		1010		
AA 5 3 9 5 6 0 9 3/7/95 A. W. STUTTLE AB 5 4 0 3 7 1 3 4/4/95 BEVILACQUA ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/28/96 NOSCO ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 5 8 9 3 9 9/4/7/98 FLANAGAN ET AL. FOREIGN PATENT SCUMENTS DOCUMENT NUMBER PATENTS CLASS SUB-TRANSLATION CLASS YES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AN 9 8 1 6 2 5 6 8/23/98 WO AK 9 8 1 6 2 5 6 8/23/98 WO OTHER DOCUMENTS (Including Blor, Title, Date, Pertinent Pages, Etc.) Hu et al., 1994, Cassogy Research, 6, 7, 321-327. AN O'Reilly et al., Cassogy Research,				<u>U. S</u>	<u>s. f</u>	PAT	EN.	TC	000	UMENTS	EMA		CLASS	SUB-	FILING	DATE
AA 5 3 9 5 6 0 9 3/7/95 A. W. STUTLE AB 5 4 0 3 7 1 3 4/4/95 BEVILACUA ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 1/28/96 NOSCO ET AL AE 5 5 5 6 9 3 9 9 M 7/96 FLANAGAN ET AL FOREIGN PATENTSOCUMENTS DOCUMENT NUMBER DATE COUNTRY AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AI 9 7 2 3 4 8 0 1/2/297 WO AJ 9 8 1 4 2 2 0 1/2/297 WO AK 9 8 1 6 2 5 5/04/23/98 WO OTHER DOCUMENTS (Including flor, Title, Date, Perlinent Pages, Etc.) AN O'Reilly et al., College, 73 15-328 Call 1 (19 7) AO Folkman, J., Natineciciene, 1995, 1, 27-31 National AD Street, 1995, 1, 1623-1634 AT Abstract, 5/1995 A. Med., Proceeding of the 42 rd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al Street, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED LOCAL MEET PROCEED THROUGH IN THE LOCAL CAPPER CONSIDERED LOCAL MEET PROCEED THROUGH IN THE LOCAL CAPPER C			DO	CUI	MEI	VI L	NON	IBE	n	DATE	NAIVIE					
AB 5 4 0 3 7 1 3 4/4/95 BEVILACQUA ET AL. AC 5 4 1 2 1 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/2/95 NOSCO ET AL AD 5 5 5 6 9 3 9 9 NA 7/96 FLANAGAN ET AL FOREIGN PATENTS COUNTRY CLASS SUB-TRANSLATION CLASS VES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/2/2/97 WO AI 9 7 2 3 4 8 0 7/97 WO AI 9 8 1 4 2 2 0 1/9/98 WO AK 9 8 1 6 2 5 5 6/4/2/3/98 WO OTHER DOCUMENTS (Including input, Title, Date, Pertinent Pages, Etc.) Hu et al., 1994, Qarrigy Research, 6, 7, 321-327. O'Reilly et al., elegat, 19, 315-328 AN O'Reilly et al., elegat, 19, 315-328 AD Folkman, J. National Cline, Invest., 1994, 93, 662-670 AD Burrows et al., 1995, 1, 27-31 NAN AS Burris et al., Cling in Res., 1995, 1, 1623-1634 AS Burris et al., Cling in Res., 1995, 1, 1623-1634 AD Friedlander et al., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED LO AU Friedlander et al., 1995, 270, 1500-2 EXAMINER	ITIAL	i	}												APPRO	PHIATE
AB 5 4 0 3 7 1 3 4/4/95 BEVILACQUA ET AL. AC 5 4 1 2 1 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/2/95 NOSCO ET AL AD 5 5 5 6 9 3 9 9 NA 7/96 FLANAGAN ET AL FOREIGN PATENTS COUNTRY CLASS SUB-TRANSLATION CLASS VES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/2/2/97 WO AI 9 7 2 3 4 8 0 7/97 WO AI 9 8 1 4 2 2 0 1/9/98 WO AK 9 8 1 6 2 5 5 6/4/2/3/98 WO OTHER DOCUMENTS (Including input, Title, Date, Pertinent Pages, Etc.) Hu et al., 1994, Qarrigy Research, 6, 7, 321-327. O'Reilly et al., elegat, 19, 315-328 AN O'Reilly et al., elegat, 19, 315-328 AD Folkman, J. National Cline, Invest., 1994, 93, 662-670 AD Burrows et al., 1995, 1, 27-31 NAN AS Burris et al., Cling in Res., 1995, 1, 1623-1634 AS Burris et al., Cling in Res., 1995, 1, 1623-1634 AD Friedlander et al., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED LO AU Friedlander et al., 1995, 270, 1500-2 EXAMINER	$\frac{1}{2}$						\top									
AB 5 4 0 3 7 1 3 4/4/95 BEVILACOUA ET AL. AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/28/96 NOSCO ET AL AE 5 5 5 6 9 3 9 NOSCO ET AL FOREIGN PATENTOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-TRANSLATION CLASS YES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 1/22/97 WO AI 9 7 2 3 4 8 0 1/2/27 WO AJ 9 8 1 4 2 2 0 1/2/2/98 WO AK 9 8 1 6 2 5 6/4/23/98 WO OTHER DOCUMENTS (Including floor, Tale, Date, Pertinent Pages, Etc.) Hu et al., 1994, 28/6/97 Research, 6, 7, 321-327. OCCCC.) AN O'Reilly et al., Cellagraf, 73, 315-328 CLI, 1994 AO Folkman, J., Nationedictione, 1995, 1, 27-31 National Country Pages,	L U	AA	5	3	9	5	6	0	9	3/7/95	A. W. S	TUTTLE			 	
AC 5 4 1 2 1 4 8 5/2/95 KEANA AD 5 5 2 0 9 0 4 5/2/8/96 NOSCO ET AL AE 5 5 15 8 9 3 9 947/96 FLANAGAN ET AL FOREIGN PATENTIO COUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS VES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 12/2/97 WO AH 9 7 2 3 4 8 0 1/8/97 WO AJ 9 8 1 4 2 2 0 1/8/97 WO AJ 9 8 1 4 2 2 0 1/8/98 WO OTHER DOCUMENTS (Including floor, Title, Date, Pertinent Pages, Etc.) Hu et al., 1994, Passoy Research, 6, 7, 321-327. On Colory AN O'Reilly et al., 2994, 79, 315-328 Call 1, (794) AO Folkman, J., National Countrolled Release, 28, 7, 195-202 AR Thorpe et al., 1995, 1, 27-31 No Burriss et al., 119, Journal of Controlled Release, 28, 7, 195-202 AR Abstract, 5/1995, 1, 1623-1634 AT Abstract, 5/1995, 1, 1623-1634 DATE CONSIDERED O AU Friedlander et al., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED O AU Friedlander et al., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED O AU Friedlander et al., 1995, 270, 1500-2 EXAMINER	1						1			·		00UA ET AL			1	
AD 5 5 2 0 9 0 4 \$5/28/96 NOSCO ET AL AD 5 5 2 0 9 0 4 \$5/28/96 NOSCO ET AL AE 5 5 5 6 9 3 3 9 \$M7/96 FLANAGAN ET AL FOREIGN PATENTOCUMENTS DOCUMENT NUMBER DATE CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION VES NO AG 9 7 1 6 4 7 4 \$5/9/97. WO AH 9 7 1 8 2 0 7 \$9/9/97. WO AH 9 7 1 8 2 0 7 \$9/9/97. WO AJ 9 8 1 4 2 2 0 \$1/9/98. WO AK 9 8 1 6 2 5 \$6/42/29/98. WO AK 9 8 1 6 2 5 \$6/42/29/98. WO OTHER DOCUMENTS (Including flyor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 29/50/97 Research, 6, 7, 321-327. On Calcol AN O'Reilly et al., 1994, 29/50/97 Research, 6, 7, 321-327. On Calcol AN O'Reilly et al., 1994, 19 3 15-328 CALL, 1994, 19 3	}	AB	5	4	0	3	7	1	3	4/4/95	BEVILA	CQUA ET AL.	 		 	
AD 5 5 2 0 9 0 4 \$5/28/96 NOSCO ET AL AD 5 5 2 0 9 0 4 \$5/28/96 NOSCO ET AL AE 5 5 5 6 9 3 3 9 \$M7/96 FLANAGAN ET AL FOREIGN PATENTOCUMENTS DOCUMENT NUMBER DATE CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION CLASS SUB- TRANSLATION VES NO AG 9 7 1 6 4 7 4 \$5/9/97. WO AH 9 7 1 8 2 0 7 \$9/9/97. WO AH 9 7 1 8 2 0 7 \$9/9/97. WO AJ 9 8 1 4 2 2 0 \$1/9/98. WO AK 9 8 1 6 2 5 \$6/42/29/98. WO AK 9 8 1 6 2 5 \$6/42/29/98. WO OTHER DOCUMENTS (Including flyor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 29/50/97 Research, 6, 7, 321-327. On Calcol AN O'Reilly et al., 1994, 29/50/97 Research, 6, 7, 321-327. On Calcol AN O'Reilly et al., 1994, 19 3 15-328 CALL, 1994, 19 3			1			_					I IZE ANIA			-	1	
AE 5 5 5 6 9 3 9 9 47/96 FLANAGAN ET AL FOREIGN PATENTIFICUMENTS CLASS SUB-TRANSLATIO CLASS YES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 122/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 8 1 6 2 5 6 94/23/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Hu et al., 1994, 93/69/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Hu et al., 1994, 93/69/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Folkman, J., Jaket Medicine, 1995, 1, 27-31 NAU O'Reilly et al., Celled, 1995, 1, 27-31 NAU Takashima, S., Jaket Medicine, 1995, 1, 27-31 NAU Takashima, S., Jaket Medicine, 1995, 1, 27-31 AG Burrows et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 19		AC	5	4	1	2	1	4	8	5/2/9 5	KEANA		 		1	
AE 5 5 5 6 9 3 9 9 47/96 FLANAGAN ET AL FOREIGN PATENTIFICUMENTS CLASS SUB-TRANSLATIO CLASS YES NO AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 122/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 7 2 3 4 8 0 1/8/97 WO AI 9 8 1 6 2 5 6 94/23/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Hu et al., 1994, 93/69/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Hu et al., 1994, 93/69/98 WO OTHER DOCUMENTS (Including floar, Title, Date, Perlinent Pages, Etc.) AM Folkman, J., Jaket Medicine, 1995, 1, 27-31 NAU O'Reilly et al., Celled, 1995, 1, 27-31 NAU Takashima, S., Jaket Medicine, 1995, 1, 27-31 NAU Takashima, S., Jaket Medicine, 1995, 1, 27-31 AG Burrows et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1/3/1/Journal of Controlled Release, 28, 1, 19		}	\ _	_					1	T/00/06	NOSCO) FT AI	ĺ	_		
FOREIGN PATENTISCUMENTS		AD	15	15	12	10	9	0	7	10120/90·	110000) L () (L	 			
FOREIGN PATENTISCUMENTS	\bigcirc	١	1-	_	_	6	a	3	9	19/17/96	FLANA	GAN ET AL			<u> </u>	
DOCUMENT NUMBER BATE COUNTRY CLASS SUB- INVESTIGATION CLASS SUB- INVESTIGATION CLASS SUB- INVESTIGATION CLASS SUB- INVESTIGATION SUB- INVESTIGATION CLASS SUB- INVESTIGATION	-NU)	AE	13	FO	믉	IGN	J P	ATE	EN	DOCUMEN						=
AF 9 7 0 8 1 4 5 3/6/97 WO AG 9 7 1 6 4 7 4 5/9/97 WO AH 9 7 1 8 2 0 7 3/22/97 WO AI 9 7 2 3 4 8 0 3/29/97 WO AJ 9 8 1 4 2 2 0 5/9/98 WO AK 9 8 1 6 2 5 6 3/2/3/98 WO OTHER DOCUMENTS (Including flor, Title, Date, Pertinent Pages, Etc.) AN O'Reilly et al., Cetted, 7, 321-327. Oncocy AN O'Reilly et al., Cetted, 79, 315-328 Cell 1994 AO Folkman, J., Netwindicine, 1995, 1, 27-31 Novel 1	COUNTRY CLASS SUB- TRANSLATION															
AG 9 7 1 6 4 7 4 5/9/97. WO AH 9 7 1 8 2 0 7 1/22/97. WO AI 9 7 2 3 4 8 0 1/3/97. WO AJ 9 8 1 4 2 2 0 1/9/98. WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Includingsfor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Qarogy Research, 6, 7, 321-327. Oncology AN O'Reilly et al., Celips4, 79, 315-328 Cell 1994 AO Folkman, J., Nate Medicine, 1995, 1, 27-31 Natural AP Takashima, S. 28/3. Cline. Invest., 1994, 93, 662-670 Cell 1994 AR Thorpe et al., 1997 reast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 M. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. The pages, 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2	CLASS YES NO															
AG 9 7 1 6 4 7 4 5/9/97. WO AH 9 7 1 8 2 0 7 1/22/97. WO AI 9 7 2 3 4 8 0 1/3/97. WO AJ 9 8 1 4 2 2 0 1/9/98. WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Includingsfor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Qarogy Research, 6, 7, 321-327. Oncology AN O'Reilly et al., Celips4, 79, 315-328 Cell 1994 AO Folkman, J., Nate Medicine, 1995, 1, 27-31 Natural AP Takashima, S. 28/3. Cline. Invest., 1994, 93, 662-670 Cell 1994 AR Thorpe et al., 1997 reast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 M. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. The pages, 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2 Cent 1995, 270, 1500-2	$\overline{}$	+	+	\top	T				"		T			- _	1	i
AH 9 7 1 8 2 0 7 122/97 WO AI 9 7 2 3 4 8 0 139/97 WO AJ 9 8 1 4 2 2 0 199/98 WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Includings nor, Title, Date, Pertinent Pages, Etc.) AN Hu et al., 1994, 2 13 15 328 Cell, 1914 AO Folkman, J., Nationedicine, 1995, 1, 27-31 Nationed Cine, 1994, 93, 662-670 Cel 1 AO Burrows et al., 1915, Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1916, 68-5, 1995, 1, 1623-1634 AT Abstract, 5/1995, 15, Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P EXAMINER DATE CONSIDERED LO 2 LO 2	204	AF	- 9		7	0 8	1	4	5	3/6/97	wo				+	
AH 9 7 1 8 2 0 7 122/97 WO AI 9 7 2 3 4 8 0 139/97 WO AJ 9 8 1 4 2 2 0 199/98 WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Includings nor, Title, Date, Pertinent Pages, Etc.) AN Hu et al., 1994, 2 13 15 328 Cell, 1914 AO Folkman, J., Nationedicine, 1995, 1, 27-31 Nationed Cine, 1994, 93, 662-670 Cel 1 AO Burrows et al., 1915, Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1916, 68-5, 1995, 1, 1623-1634 AT Abstract, 5/1995, 15, Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P EXAMINER DATE CONSIDERED LO 2 LO 2																- 1
Al 9 7 2 3 4 8 0 1/3/97 WO AJ 9 8 1 4 2 2 0 1/3/98 WO AK 9 8 1 6 2 5 6 24/23/98 WO OTHER DOCUMENTS (Including par, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 0/2/9/98 WO OTHER DOCUMENTS (Including par, Title, Date, Pertinent Pages, Etc.) AN O'Reilly et al., Colleged, 79, 315-328 Call 1/914 AO Folkman, J., Nation dedictine, 1995, 1, 27-31 Killy July 1 AP Takashima, S., 25 3: Cline. Invest., 1994, 93, 662-670 et al. AP Thorpe et al., 1995 fast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 ff. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P EXAMINER DATE CONSIDERED LO 2 DETECTION of the title before a with MEP 609: Draw line through citation if not in																
Al 9 7 2 3 4 8 0 1/3/97 WO AJ 9 8 1 4 2 2 0 1/3/98 WO AK 9 8 1 6 2 5 6 24/23/98 WO OTHER DOCUMENTS (Including par, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 0/2/9/98 WO OTHER DOCUMENTS (Including par, Title, Date, Pertinent Pages, Etc.) AN O'Reilly et al., Colleged, 79, 315-328 Call 1/914 AO Folkman, J., Nation dedictine, 1995, 1, 27-31 Killy July 1 AP Takashima, S., 25 3: Cline. Invest., 1994, 93, 662-670 et al. AP Thorpe et al., 1995 fast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 ff. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P EXAMINER DATE CONSIDERED LO 2 DETECTION of the title before a with MEP 609: Draw line through citation if not in															٠	
AJ 9 8 1 4 2 2 0 169/98. WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Including floor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 98/09/98 Besearch, 6, 7, 321-327. O'Reilly et al., 2014, 99/99 AO Folkman, J., National dictine, 1995, 1, 27-31 No. 101 AP Takashima, S., 21 Cline. Invest., 1994, 93, 662-670 CHOLOND AQ Burrows et al., 1995, 1, 1623-1634 AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 M. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P LICAL AU Friedlander et al. 1995, 270, 1500-2 SCENCIL DATE CONSIDERED U Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q Q D DATE CONSIDERED U Q Q Q Q Q Q I not in the process with MPEP 609: Draw line through citation if not in		AH	1 9	7	7	1 8	3 2	2 0	4	19722/97	WO.					
AJ 9 8 1 4 2 2 0 169/98. WO AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Including floor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 98/09/98 Besearch, 6, 7, 321-327. O'Reilly et al., 2014, 99/99 AO Folkman, J., National dictine, 1995, 1, 27-31 No. 101 AP Takashima, S., 21 Cline. Invest., 1994, 93, 662-670 CHOLOND AQ Burrows et al., 1995, 1, 1623-1634 AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 M. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P LICAL AU Friedlander et al. 1995, 270, 1500-2 SCENCIL DATE CONSIDERED U Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q D DATE CONSIDERED U Q Q Q Q Q D DATE CONSIDERED U Q Q Q Q Q Q I not in the process with MPEP 609: Draw line through citation if not in		1	. 1.	. │.	_ \			.	١	10/07	WOS				<u> </u>	
AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Including Page), Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Qanogy Research, 6, 7, 321-327. O'Reilly et al., College, Pertinent Pages, Etc.) AN O'Reilly et al., College, 1995, 1, 27-31 AO Folkman, J., Natamidedicine, 1995, 1, 27-31 AP Takashima, S., Lett.; Cline. Invest., 1994, 93, 662-670 C-d. AQ Burrows et al., 14 Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1995 feast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 ff. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. There, 1995, 270, 1500-2 SCENCE DATE CONSIDERED Q Q (D) DATE CONSIDERED		A	119	+	4	2	3 1	+ 10	+	11/8/9/	1,440,2				_	
AK 9 8 1 6 2 5 6 04/23/98 WO OTHER DOCUMENTS (Including Page), Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Qanogy Research, 6, 7, 321-327. O'Reilly et al., College, Pertinent Pages, Etc.) AN O'Reilly et al., College, 1995, 1, 27-31 AO Folkman, J., Natamidedicine, 1995, 1, 27-31 AP Takashima, S., Lett.; Cline. Invest., 1994, 93, 662-670 C-d. AQ Burrows et al., 14 Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1995 feast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 ff. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. There, 1995, 270, 1500-2 SCENCE DATE CONSIDERED Q Q (D) DATE CONSIDERED	(٠١,		اه	4	<u>a</u> :	2 2	0	0.00/98	lwo:					
OTHER DOCUMENTS (Including fror, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, 200 y Research, 6, 7, 321-327. Oncocy AN O'Reilly et al., Cessay, 79, 315-328 Cell, 1994 AO Folkman, J., Natsinedicine, 1995, 1, 27-31 Natsinedicine, 1995, 1, 27-31 AP Takashima, S. 2013. Cline. Invest., 1994, 93, 662-670 Chall AQ Burrows et al., 1997 reast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. 1995, 270, 1500-2 EXAMINER DATE CONSIDERED O CHALL DATE CONSIDERED	}	-+^	J 	+	4	-+	+	- -	+	7				_	.	ŀ
OTHER DOCUMENTS (Including fror, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Parogy Research, 6, 7, 321-327. Oncocy AN O'Reilly et al., Cassa, 79, 315-328 Cell, 1994 AO Folkman, J., Natsinedicine, 1995, 1, 27-31 Natsinedicine, 1995, 1, 27-31 AP Takashima, S. Jacki. Cline. Invest., 1994, 93, 662-670 Cell AQ Burrows et al., 111, Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1997, 1, 1623-1634 AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. 1995, 270, 1500-2 EXAMINER DATE CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED O CONSIDERED O CONSIDERED O CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED O COCY DATE CONSIDERED		ΙΔ	K	9	8	1	6	2	5	6 04/23/98	wo					
OTHER DOCUMENTS (Including figor, Title, Date, Pertinent Pages, Etc.) AM Hu et al., 1994, Oxogy Research, 6, 7, 321-327. Oncolory AN O'Reilly et al., Carsay, 79, 315-328 Call, 1994, 93, 315-328 Call, 1995, 1, 27-31 National of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1995, 200, 200, 200, 200, 200, 200, 200, 20			_	_	7					1			_	_	-	į
AM Hu et al., 1994, 1995, 1995, 1, 21-327. O'Reilly et al., Colored J. 1995, 1, 27-31 AO Folkman, J., Nats Medicine, 1995, 1, 27-31 AP Takashima, S. 2012. Cline. Invest., 1994, 93, 662-670 CHOLD AQ Burrows et al., 1997; Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1997; Res., 1995, 1, 1623-1634 AS Burris et al., Climate Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 11. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 1 82				9	8	4	7	5	4	0/29/98	<u>wo</u>					
AM Hu et al., 1994, 1995, 1995, 1, 21-327. O'Reilly et al., Colored J. 1995, 1, 27-31 AO Folkman, J., Nats Medicine, 1995, 1, 27-31 AP Takashima, S. 2012. Cline. Invest., 1994, 93, 662-670 CHOLD AQ Burrows et al., 1997; Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1997; Res., 1995, 1, 1623-1634 AS Burris et al., Climate Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 11. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 1 82		 														
Oncocy O'Reilly et al., Ceis94, 79, 315-328 Cell, 1994 AO Folkman, J., Natwickicine, 1995, 1, 27-31 AP Takashima, S., Sayl. Cline. Invest., 1994, 93, 662-670 Cell AQ Burrows et al., 1995 Cline. Invest., 1994, 93, 662-670 Cell AR Thorpe et al., 1995 Cline. Research & Treatment, 36, 2, 237-251. AS Burris et al., Cline. Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 Cl. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Res., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED Log Log Date through citation if not in	01	THEF	R DO	<u> </u>	JM	EN.	<u>TS</u>	(Inc	lud	ing for, Title	e, Date, Pe	ertinent Pages, Etc.)				
AN O'Reilly et al., Ceiss4; 79, 315-328 Cell, 1994 AO Folkman, J., Nationedicine, 1995, 1, 27-31 National AP Takashima, S., et al., 1 Cline. Invest., 1994, 93, 662-670 et al., 1995, 1 Cline. Invest., 1994, 93, 662-670 AR Thorpe et al., 1995, 200 Controlled Release, 28, 1, 195-202 AR Burris et al., Cline Res., 1995, 1, 1623-1634 AS Burris et al., Cline Res., 1995, 1, 1623-1634 AT Abstract, 5/1995, 21. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED O DATE CONSIDERED O DATE CONSIDERED O DATE CONSIDERED		AM	1		Ηι	u et	al.,	, 19	94,	One ogy He	search, t	5, 7, 321-327.				
AO Folkman, J., Nationedicine, 1995, 1, 27-31 AP Takashima, S., and J. Cline. Invest., 1994, 93, 662-670 C+Q1 AQ Burrows et al., 121, Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1997 east Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cline. Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Res., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED LOCATION CONSIDER	900	<u> </u>			١		111					}				
AO Folkman, J., Nationedicine, 1995, 1, 27-31 AP Takashima, S., 21. Cline. Invest., 1994, 93, 662-670 e-10. AQ Burrows et al., 12. Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1997 reast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 1. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Shee, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 (02) DATE CONSIDERED U 2 (02) DATE CONSIDERED	_ (AN	1		١٥	He	шу	ela				,				
AP Takashima, S. e. J. Cline. Invest., 1994, 93, 662-670 C+Q1 AQ Burrows et al., 1995, Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 1995, East Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Cling Res., 1995, 1, 1623-1634 AT Abstract, 5/1995, Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Fr	 	100	\leftarrow		\ <u>-</u>	olkr	nar					1, 27-31				
AP Takashima, S. Lef J. Cline. Invest., 1994, 93, 662-670 C+G I AQ Burrows et al., 19 Journal of Controlled Release, 28, 1, 195-202 AR Thorpe et al., 19 Freast Cancer Research & Treatment, 36, 2, 237-251. I 1975, Burst AS Burris et al., Cline. Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Res., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED Q 2 (D2) DATE CONSIDERED Q 2 (D2) DATE CONSIDERED		AC	1		1				4	Jalune 9						
Burrows et al., 19 Freast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Clima Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Res., 1995, 270, 1500-2 EXAMINER DATE CONSIDERED Up 2 (Day) DATE CONSIDERED Up 2 (Day) DATE CONSIDERED Up 2 (Day) DATE CONSIDERED	 	+ AF	- +		╁	aka	shi	ma	, s.	J. Clin	e. Invest.	., 1994 , <i>93</i> , 662-670				
AR Thorpe et al., 19 Freast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Clima Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Ree, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 (22) DATE CONSIDERED U 2 (22) EXAMINER	1	^'	- 1		1					etai						
AR Thorpe et al., 19 Freast Cancer Research & Treatment, 36, 2, 237-251. AS Burris et al., Clima Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 St. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Ree, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 (22) DATE CONSIDERED U 2 (22) EXAMINER		A	a †		Te	Burr	ows	et	al.,	1/1, Journ	nal of Cor	ntrolled Release, 28,	<i>1</i> , 195-20	2		
AS Burris et al., Clima Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 I. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Ree, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 1 82					- 1											
AS Burris et al., Clima Res., 1995, 1, 1623-1634 AT Abstract, 5/1995 I. Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al. Ree, 1995, 270, 1500-2 EXAMINER DATE CONSIDERED U 2 1 82	-	A	R		1	ho	rpe	et a	al.,	19 reast	Cancer R	esearch & Treatmen	τ, <i>36, 2</i> , 2	3/-251.		
AT Abstract, 5/1995 Med., Proceeding of the 42 nd Annual Meeting, 36, 5, no. 287, 71P AU Friedlander et al Friedlander					l					1495/Brea	ST					
AU Friedlander et al. Friedlande	AS Burris et al., Cling Res., 1995, 1, 1623-1634															
AU Friedlander et al. Friedlande																
EXAMINER DATE CONSIDERED LOCAL DATE CONSIDE	AT Abstract, 5/1995 Med., Proceeding of the 42 Affiliativicating, 33, 3, 16. 25.															
EXAMINER DATE CONSIDERED () 2 () 82 U) 2 () 82 U) 2 () 82 U) 2 () 82 U) 3 () 82 U) 3 () 82 U) 3 () 82 U) 3 () 83 U) 3 () 84 U) 4 () 84 U) 4 () 84 U) 5 () 84 U)	4005 070 1500 2															
EXAMINER DATE CONSIDERED () 2 () 82 Date Considered with MPEP 609: Draw line through citation if not in	Signal															
EXAMINER (a) 2 (62) (b) 2 (62) (c) 3 (62) (d) 4 (62) (e) 4 (62) (f) 5 (62) (f) 6 (62) (f) 6 (62) (f) 7 (62) (f) 7 (62) (f) 8 (62) (f) 8 (62) (f) 9 (62) (f)	1	낦		ل	ᅷ							DATE CONSIDER	ED			
the state of the s	EXAMINER \(\)															
*EXAMINER: Initial if citation considered, whether citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of with next communication to applicant.				Ŋ												
conformance and not considered. Include copy of the next communication to applicant.	*EVANAINI	ER: Ir	nitial	if cit	atio	h co	nsid	erec	i, wi	netherat citatio	on is in con	formance with MPEP 609	; Draw line t	hrough citat	ion if not it	n
	conformat	nce ar	nd no	t co	nsid	lerec	i. In	clud	le co	opy of the wife	th next com	munication to applicant.				

	PTO-1				U	.s. [DEF	AR	LWE	NT OF COMM	ATTY, DOCKET NO.		SERIA		
(Repro	oduced)					PA	TEN	IT A	ND T	NT OF COMME RADEMARK O	DM-6958		09/281	1,474	
	SUPP	LEME	NT/		1141	Un	IIVI	~ ! !	OIA	DISCLOSO	TIL 37 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	ΑΙ			
								TNE		OCT 1	6 2000 RAJOPADHYE ET	AL	GROU	P	
		/I le	0 0	BY SYS	' Al	eho PPL	LIC apte	AN : if i	l nece	essa r	March 30, 1999		1616	•	
		(08	e 56	U.	S	DΦ.	TF	NT	DO	CUMENTS,			1.0.0		-
*EXAM	INER	Τ	DO	CU N						DATE	NAME	CLASS	SUB-	FILING DA	
INITIA		 		ī									CLASS	APPROPE	RIATE
R		АА	5	5_	6	7	4	1	1	10/22/96	KEANA ET AL		_		
	(AB	5	6	5	9	0	4	1	8/19/97	POLLAK ET AL.				
		AC	5	6	5	9	0	1	3	8/19/97	SENGER ET AL.				
		AD	5	6	6	0	8	2	7	8/26/97	THORPE ET AL.				
K	0	AE		6						7/22/97	ALBERT ET AL	•	_		
			F	FOF	REI	GN	P/	ATE	NT	DOCUMEN					
	DOCUMENT NUMBER DATE COUNTRY CLASS SUB-TRANSLATION CLASS YES NO														
7.															
	AF 9 9 0 6 0 4 9 2/11/99 WO AG 9 9 1 3 3 2 9 3/18/99 WO AH 9 9 4 0 9 4 7 8/19/99 WO														
	AG 9 9 1 3 3 2 9 3/18/99 WO														
	AG 9 9 1 3 3 2 9 3/18/99 WO AH 9 9 4 0 9 4 7 8/19/99 WO AI 0 1 0 7 7 3 4 7/29/87 EP														
	AH 9 9 4 0 9 4 7 8/19/99 WO AI 0 1 0 7 7 3 4 7/29/87 EP														
1															
K	XX	AL	0	4	3					10/07/91	EPO			-	
	- - 1TO		•								Date, Pertinent Pages, Etc.)	•			
4	\bigcap										996, 61, 903-908				
1	' 	AM		K.	ren	nin	a e	اد ا	Di	réstion 100	6, 57, 57-61				
1	'	AN		^	CII	1 111 1	y e	ı di.	, וט	y c ouon, 139	o, or, or-or				
	-	- " -		10	'Re	illy	et	al.,	Cell	, 1997 , 88, 2	277-285			-	_
		AO													
		AP									, 53, 11937-11952				
		AQ		S	eng	jer,	et	al.,	Pro	c. Natl. Acad	d, Sci USA, 1997 , 94, 13612-	7			
		AR		Н	aut	ne	r, ∖	/31	3 Ni	ıclear-Mediz	rin, March/1997.				
		AS		S	riva	itsa	et	al.,	Ca	rdiovascular	Res. 1997 , <i>36</i> , 408-428.				
		AT		H	orto	on e	et a	ıl., P	May	1997, Int. J.	Biochem. Cell. Biol. 29, 5, 72	21-725.			
10		AU		0	lso	n e	t al	., Ir	nt. J.	Cancer, 19	97 , <i>73</i> , 865-870.				
EXAN	EXAMINER DATE CONSIDERED														
	,	_	1	5	_	10	n	بھ	2		6/21/00	_			
*EXAM	MINER: I	Initial if Ind not	/ citati cons	ion d	ons ed.	/ ider Incl	ed, ude	whe	ther y of t	or not citation i his form with n	s in conformance with MPEP 609; Dext communication to applicant.	raw line thro	ugh citati	on if not in	

Sheet <u>5</u> of <u>7</u>

Form PTO-1449 U.S. DEPARTMENT OF COMMERC ATTY. DOCKET NO DM-6958 SUPPLEMENTAL INFORMATION DISCLOSURE APPLICANT APPLICANT														SERIAL		
			ENIT		i Nac	PAT	EN7	Γ ΑΝ NEL	ID TE	RADIZMANK O	FFICE O	DM-6958		09/281	,4/4	
5	UPP	LEWI	= N I /		TA	TE	IVI <i>F</i> N/I ⊯	NT	JNI	DISCLUSUR OCT 1	೯೨೧೧೧ 1⊏ ಡ್/	RAJOPADHYE ET	ΓΔΙ			
											ס צטטט פי	FILING DATE		GROUP		
		(Us	se se	ver	al s	he	ets	if n	ece	ssarti.	. S.	March 30, 1999		1616		
				U. S	S. F	AT	EN	IT [OC	UMENT SPA	DEMARK			<u> </u>		
*EXAMIN	ER		DC	CUI	MEN	JT N	UM	BEF	}	DATE	NAME		CLASS		FILING DA	
INITIAL	$\overline{}$				r -		г				<u>. </u>			CLASS	APPROPE	RIATE
90(ノ		5		7	9		4	0	10/21/97	LOVE ET	T AI	·			
	-+	AA	+3	6	+	9	8	1	0	10/21/97	LOVEL	1 AL	 			
]	`	AB	5	7	6	0	1	9	1	6/2/98	SNOW E	T AI				
		1	1-	Ť	Ť	Ť				<u> </u>	<u> </u>					
		AC	5	7	6	0	0	2	8	6/2/98	JADHAV	ET AL				
		AD	5	7	6	6	5	9	1	6/16/98	BROOKS	S ET AL.				
	1		ļ											_		
\ <u>\</u>	<u>V</u>	AE	5	7	7	6	4	2	7	7/7/98	THORPE	E ET AL.				
\mathcal{A}	$\langle \lambda \rangle$	AF	_					_		0/0/00		Τ ΔΙ		<u> </u>		
	<u> </u>	AF	<u> 5</u>			4				9/8/98 DOCUMENT	LONG E	IAL				
		Т		CU						DATE	COUNTR	Υ	CLASS	SUB-	TRANS	LATION
				-						27.112			02.100			NO
	AG 0 7 2 7 2 2 5 8/21/96 EP (A2) AH 5 3 1 4 6 9 4 7/21/94 AU															
M	AG 0 7 2 7 2 2 5 8/21/96 EP (A2) AH 5 3 1 4 6 9 4 7/21/94 AU															
	AH 5 3 1 4 6 9 4 7/21/94 AU															
	AH 5 3 1 4 6 9 4 7/21/94 AU															
	Al 2 0 3 9 2 5 9 10/03/91 CA AJ 2 2 3 2 3 1 5 4/10/97 CA(Corresponds to DE19536785)															
		AK	2	1	1	3	2	4	5	6/13/88	CA/Correst	oonds to WO0606683))			-	
	1,	 	+-	†	††		-			0/10/00	OA(COITES)	bonds to vv Coccoccoji			+	
	lf –	AL	2	1	5	6	6	2	0	10/14/94	CA Corres	ponds to WO94/22497)		_		
	4													T		
, M	Δ	AM	4	3	1	1	0	2	3	10/6/94	DE (Corres	sponds to WO9422497)		<u> </u>		
	\	\														
<u> </u>	OTH	IER D	OCI									nent Pages, Etc.)				
in/	Λ	AA.		S	ıpkı	ns	et a	al.,	Nati	ire Medicine	e, 5/1998, ·	4, 5, 623-626.				
1	11'	AN		M	ماما	ma	ot.	<u>al</u>	Rio	chemical Ph	armacolo	gy, 1998 , <i>55</i> , 1939-	1945			
	t [AO		'''	OIC	IIIa	Ci	aı.,	DIO	Chemicari	amacolo	gy, 1990, 99, 1909-	1040.			
<u> </u>		AP		K	enr	nel e	et a	ıl I	Nucl	ear Medicin	e & Bioloa	ıy, 1998 , <i>25</i> , 241-24	16.			-
	[] .	_	_	_	_	_							
		AQ		Н	enr	y, T	Г. е	t al	., (J.	Amer. Colle	ege Cardio	ology, 810-1, 1998 ,	, 31, 65A,)			
				\downarrow												
		AR		K	err	et a	al, M	Иaг	-Apı	1999 , Anti	cancer Re	esearch, , <i>19, 2A</i> , 95	58-968			
<u> </u>		•		 							00 0 100	0.4005				
,	·	AS		L	u e	t ai	., 1	999), In	org. Chem,	38, 6, 132	6-1335				
$\vdash \mathcal{H}$,	AT		-	اللم	-	+ ^!)rı ı~	s, 1999 , <i>58</i> ,	3 301-30	6				
	/ '	^'		١	CIIN		ιaı	٠, ٢	riugi	5, 1999, 50,	J, JJ 1-JJ	0.				
	T	AU		T	eN	ard	o e	t al	Fe	b. 2000 . Ca	ncer Bioth	nerapy & Radiophar	m. <i>15. 1.</i> 7	 '1-79		
I ha	入じ				•	 .			, . •	, _u			., . = , ., .	_		
EXAMI	XAMINER DATE CONSIDERED															
			,-	T.	4)	\mathcal{M}	۹	0			(0/21/	72			
-				<i>-</i> ₽	بح	4,	<i></i>					7/04/	<u> </u>			
												nce with MPEP 609; Dra cation to applicant.	aw line throu	gh citation	if not in	

Sheet 6 of 7

Form P					U					NT OF COMMI		ATTY. DOCKET NO). —		SERIAL		
(Reprodi										RADEMARK		DM-6958			09/281	,474	
S	UPP	LEME	:NI			-OF				DISCIOSU	FRE (C13)	APPLICANT RAJOPADHYE ET	ΓΔΙ				
				-	, .				_	1	91	FILING DATE	· //L	T	GROU	P	
		(Us	se se	eve	ral	she	eets	s if	nece	essary) 1	(بىر 2008 6	March 30, 1999			1616		
				U.	S.	PA	TE	NT	DO	CUMENIS	47	· · · · · · · · · · · · · · · · · · ·					
*EXAMIN INITIAL	ER		DO	CUN						DATE TRAI	NAME		CL		SUB- CLASS	FILING DA	
15	7	AA	5	8	0	1	2	2	8	9/1/98	HOLLIST	ΓER ET AL.	_	- ·	-		
1	1	АВ	5	8	5	5	8	6	6	1/5/99	THORPE	E ET AL.		_	-		
		AC	5	8	6	3	5	3	8	1/26/99	THORPE	E ET AL.	_				
		AD	6	0	4	0	3	1	1	3/21/00	DUGGA	N ET AL.	_	_			
		AE	6	0	5	1	2	0	7	4/18/00	KLAVEN	ESS ET AL			_		
//	<u> </u>	AF	6	0	5	1	2	3	0	4/18/00	THORPE	ET AL.	_				
K	7	AG				6			3	05/02/00	ALLEN E	ET AL.					
P	AH 19 5 3 6 7 8 1 3/27/97 DE (Gerresponds to WO9710852)																
R		AI	19	5	3	6	7	8	5	3/27/97	DE (Corresponds to WO972636)					<u> </u>	
1,16	AJ 19 7 2 5 3 6 8 12/17/98 DE (Corresponds to WO972636)																
		AK							ļ 				_	· · · · · -		-	
		AL								<u> </u>							
	OTH	IER D	oc	UM	ΙEΝ	ITS	(In	clu	dina	Author, Title.	Date. Pert	inent Pages, Etc.)					
		AM										irnal of Oncology, 1	6, 1	189-11	95		
10	\prod	AN		Ва	att	et a	al., :	200	0, J	. Med. Cher	n. 43, 41-	58.	-				
	\mathcal{T}	AO								22							
		AP													<u> </u>		
	1	AQ					-	-	-								
	,	AR															
	,	AS															
EXAMI	NER			_			$\overline{}$				D	ATE CONSIDERED	<u>, (</u>				
					\sum_{i}	\bigcup		4_	9	2		10/2	40	2			_
*EXAMIN conforma	IER: I	nitial if	citati consi	on c	ons ed.	ider Incl	ed, ude	whe	ther o	or not citation in his form with n	s in conform ext commun	ance with MPEP 609; Dication to applicant.	/ Praw I	ine throu	igh citatio	on if not in	